Genmab — Board/Management Information 2010

Jun 2, 2010

News Details

Corporate | 2 June 2010 14:28

Change in Constitution of the Board of Directors

Genmab A/S /

02.06.2010 14:28

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Summary: Genmab's Board of Directors to include three employee members.

Copenhagen, Denmark; June 2, 2010 - Genmab A/S (OMX: GEN) announced today that
three Genmab employees were elected to the company's Board of Directors. In
accordance with the Danish Companies Act the employees of a company are
entitled to be represented on the Board of Directors if the company has
employed a minimum of 35 employees on average over the past three years and the
employees request such representation.

The employees of Genmab A/S chose to exercise this right and in addition,
approved a voluntary arrangement, which allowed the subsidiaries of the company
to also participate in the election. As a result three Genmab employees, along
with three alternates, were elected by their peers to become members of the
Board.

Details regarding these new board members are as follows. They will join
Genmab's Board of Directors in conjunction with the June 2, 2010 Board of
Directors' Meeting.

Daniel J. Bruno
American, 30
Mr. Bruno joined Genmab in 2008 and is currently the Controller of Genmab's
locations in the United States. Before joining Genmab he spent six years at
PricewaterhouseCoopers in the Assurance and Business Advisory practice serving
clients in Health Industries group, which included pharmaceutical, life
science, and biotech companies. He is a Certified Public Accountant and
received B.S. and M.S. degrees from Fairleigh Dickinson University.

Nedjad Losic
Swedish, 41
Mr. Losic joined Genmab in 2004 and is currently Associate Director, Statistics
at Genmab's location in Copenhagen. He has worked in the pharmaceutical
industry since 1996. Prior to joining Genmab he held positions at Ferring
Pharmaceuticals and at Spadille Sweden, where he was Managing Director. He was
the responsible statistician for two successful drug applications, one in 1999
and one in 2009. He also served on the board of directors for other
non-industry associations. Mr. Losic received a M.Sc. in Mathematics from the
University of Lund and a diploma in Management of Medical Product Innovation
from the Scandinavian International Management Institute.

Tom Vink, Ph.D.
Dutch, 47
Dr. Vink joined Genmab in 2002 as Head of Molecular Biology. Currently he is
leading the Cell and Molecular Science unit at Genmab's R&D facility in
Utrecht. Before joining Genmab, Dr. Vink worked for more than 15 years in life
sciences research, specializing in molecular biology and biochemistry. Dr. Vink
is the author of over 20 scientific publications and is named inventor on over
10 patents and patent applications. He received a M.S. degree in Biochemistry
from Leiden University, and a Ph.D. from Utrecht University.

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM); HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM); HuMax-Wnt;
HuMax-cMet(TM) and UniBody(R) are all trademarks of Genmab A/S. Arzerra(R) is a
trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations, T: +45 33 44 77 30,
M: +45 25 27 47 13, E: h.husted@genmab.com

Stock Exchange Release no. 19/2010

News Source: NASDAQ OMX

02.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Denmark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of News DGAP News-Service

---